Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 3/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31185482 | 1.00 | MAPK1 (0.45) | MAPK1OPRD1OPRK1KDM1AGPR119 | |
| SCHEMBL26023996 | 0.85 | ESR2 (0.53) | OPRD1OPRK1KDM1AGPR119TSHR | |
| SCHEMBL31758771 | 0.84 | NR1H2 (0.43) | OPRD1OPRK1GPR119NR1H2USP30 | |
| SCHEMBL26023999 | 0.84 | NR1H2 (0.43) | OPRD1OPRK1GPR119NR1H2USP30 | |
| SCHEMBL21851882 | 0.84 | OPRD1 (0.43) | MAPK1OPRD1OPRK1KDM1AGPR119 | |
| SCHEMBL31758803 | 0.83 | NR1H2 (0.42) | OPRD1OPRK1GPR119NR1H2USP30 | |
| SCHEMBL20510139 | 0.81 | POLB (0.48) | MAPK1OPRD1OPRK1KDM1AGPR119 | |
| SCHEMBL22770411 | 0.81 | POLB (0.48) | OPRD1OPRK1KDM1AGPR119TSHR | |
| SCHEMBL26023995 | 0.81 | PDE4D (0.40) | OPRD1OPRK1KDM1AGPR119TSHR | |
| SCHEMBL22793098 | 0.79 | KDM1A (0.41) | MAPK1OPRD1OPRK1KDM1AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230168-A1 | AZASPIRO WRN INHIBITORS | GILEAD SCIENCES, INC. | 2025-07-17 | — | — | US | disclosed |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4506035-A2 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-3768668-B1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-117263942-A | SHP2 phosphatase inhibitors and methods of use thereof | 传达治疗有限公司 | 2023-12-22 | — | — | CN | disclosed |
| WO-2023179659-A1 | POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF | 江苏恩华药业股份有限公司 | 2023-09-28 | — | — | WO | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| CN-112166110-B | SHP2 phosphatase inhibitors and methods of use thereof | 传达治疗有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | D. E. SHAW RESEARCH, LLC | 2023-07-27 | — | — | US | disclosed |
| US-8431700-B2 | Alkylsulfonyl-2,3-dihydrospiro[indene-1,4′-piperidine] analogs as GlyT1 inhibitors, methods for making same, and use of same in treating psychiatric disorders | VANDERBILT UNIVERSITY (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120309778-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20100249167-A1 | ALKYLSULFONYL-2,3-DIHYDROSPIRO[INDENE-1,4'-PIPERIDINE] ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2010-09-30 | — | — | US | disclosed |
| US-20100249167-A1 | ALKYLSULFONYL-2,3-DIHYDROSPIRO[INDENE-1,4'-PIPERIDINE] ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2010-09-30 | — | — | US | disclosed |
| WO-2010102003-A2 | ALKYLSULFONYL-2,3-DIHYDROSPIRO[INDENE-1,4'-PIPERIDINE] ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2010-09-10 | — | — | WO | disclosed |
| US-20050038060-A1 | Spiropoperidine compounds as ligands for orl-1 receptor | ANDO KOJI (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1399432-A1 | SPIROPIPERIDINE COMPOUNDS AS LIGANDS FOR ORL-1 RECEPTOR | PFIZER INC. (US) | 2004-03-24 | — | — | EP | disclosed |
| EP-1057827-B1 | SPIROPIPERIDINE DERIVATIVES | SANKYO CO (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-6511975-B1 | Exhibit antagonistic action against tachykinin receptors | SANKYO COMPANY, LIMITED (JP) | 2003-01-28 | — | — | US | disclosed |
| WO-2003000677-A1 | SPIROPIPERIDINE COMPOUNDS AS LIGANDS FOR ORL-1 RECEPTOR | PFIZER PHARMACEUTICALS INC. (JP) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230168-A1 | AZASPIRO WRN INHIBITORS | WRN, RECQL, BLM | MAPK1 3308/4885OPRD1 4696/4885OPRK1 4577/4885 |
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | MAPK1 458/4885OPRD1 4596/4885OPRK1 4648/4885 |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | MAPK1 1518/4885OPRD1 708/4885OPRK1 1495/4885 |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | MAPK1 458/4885OPRD1 4596/4885OPRK1 4648/4885 |
| US-20120309778-A1 | Fused and Spirocycle Compounds and the Use Thereof | CACNA1A, CACNA1E, CACNA1C | MAPK1 3078/4885OPRD1 123/4885OPRK1 129/4885 |
| US-20050038060-A1 | Spiropoperidine compounds as ligands for orl-1 receptor | OPRL1, OXER1, OGFRL1 | MAPK1 743/4885OPRD1 5/4885OPRK1 13/4885 |
| US-20100249167-A1 | ALKYLSULFONYL-2,3-DIHYDROSPIRO[INDENE-1,4'-PIPERIDINE] ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS | SLC1A2, SLC1A1, SLC1A3 | MAPK1 2464/4885OPRD1 640/4885OPRK1 740/4885 |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | MAPK1 458/4885OPRD1 4596/4885OPRK1 4648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.